Age
Item
men and women who are ≥ 50 and ≤ 85 years old
boolean
C0001779 (UMLS CUI [1])
Non-Insulin-Dependent Diabetes Mellitus Disease length
Item
subjects diagnosed with type 2 diabetes at least 2 years prior to screening
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Diabetic Nephropathy | Chronic kidney disease stage
Item
subjects with diabetic nephropathy and ckd stage 3b-4
boolean
C0011881 (UMLS CUI [1])
C2074731 (UMLS CUI [2])
Urine albumin/creatinine ratio measurement Spot urine sample
Item
albumin-to-creatinine ratio (acr) from a spot urine sample >30 and < 3000 mg/g at screening
boolean
C0455271 (UMLS CUI [1,1])
C0457208 (UMLS CUI [1,2])
Standard of Care Diabetic Nephropathy | Angiotensin-Converting Enzyme Inhibitors | Angiotensin II receptor antagonist
Item
subjects must be receiving standard of care treatment for their diabetic nephropathy with an angiotensin converting enzyme inhibitor (acei) and/or an angiotensin ii receptor blocker (arb) for at least 12 weeks prior to screening.
boolean
C2936643 (UMLS CUI [1,1])
C0011881 (UMLS CUI [1,2])
C0003015 (UMLS CUI [2])
C0521942 (UMLS CUI [3])
Hemoglobin A1c measurement
Item
hba1c < 10.0% at screening
boolean
C0474680 (UMLS CUI [1])
Study Subject Participation Status | Stem cell Clinical Trial
Item
prior participation in any stem cell study
boolean
C2348568 (UMLS CUI [1])
C0038250 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
Childbearing Potential
Item
women of childbearing potential
boolean
C3831118 (UMLS CUI [1])
Study Subject Participation Status Unreliable | Study Subject Participation Status Inappropriate
Item
potentially unreliable subjects and those judged by the investigator to be unsuitable for the study
boolean
C2348568 (UMLS CUI [1,1])
C4061925 (UMLS CUI [1,2])
C2348568 (UMLS CUI [2,1])
C1548788 (UMLS CUI [2,2])
Substance Use Disorders | Consumption Alcoholic Beverages U/day | Consumption Alcoholic Beverages U/week
Item
history of active substance abuse (including alcohol) within the past 2 years. current alcohol abuse is defined as daily consumption of >3 alcoholic beverages (i.e. > 21 alcoholic beverages per week)
boolean
C0038586 (UMLS CUI [1])
C0001948 (UMLS CUI [2,1])
C0001967 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0001948 (UMLS CUI [3,1])
C0001967 (UMLS CUI [3,2])
C0560588 (UMLS CUI [3,3])
Body Weight
Item
body weight >150 kg
boolean
C0005910 (UMLS CUI [1])
Kidney Disease | Diabetes Mellitus Absent | Polycystic Kidney Disease
Item
subjects with non-diabetic renal disease e.g. known polycystic kidney disease
boolean
C0022658 (UMLS CUI [1])
C0011849 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0022680 (UMLS CUI [3])
Kidney Transplantation | Dialysis | Renal function Stable Lacking
Item
subjects with a history of a renal transplant or who have had prior dialysis within 3 months of screening and/or have not maintained a stable level of kidney function within 3 months of screening
boolean
C0022671 (UMLS CUI [1])
C0011946 (UMLS CUI [2])
C0232804 (UMLS CUI [3,1])
C0205360 (UMLS CUI [3,2])
C0332268 (UMLS CUI [3,3])
Heart failure New York Heart Association Classification
Item
current or history within 6 months of screening of nyha class iii or iv heart failure
boolean
C0018801 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Myocardial Infarction | Cerebrovascular accident
Item
myocardial infarction or stroke within 6 months prior to screening
boolean
C0027051 (UMLS CUI [1])
C0038454 (UMLS CUI [2])
Comorbidity Interferes with Completion of clinical trial | Cardiovascular Disease Symptomatic | Gastrointestinal Diseases | Hematological Disease | Lung diseases | Communicable Disease | Chronic infectious disease | Retinal Diseases | Therapy Affecting Evaluation | Therapy Study Subject Participation Status Excluded
Item
any concurrent medical condition/disorder or clinically symptomatic cardiovascular, gastrointestinal, hematological, pulmonary, acute or chronic infectious disease, active retinal disease or other disorder which in the investigator's opinion would interfere with the subjects ability to complete the trial, would require administration of treatment that could affect the interpretation of the efficacy and safety variables or would preclude safe involvement in the study
boolean
C0009488 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C2732579 (UMLS CUI [1,3])
C0007222 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
C0017178 (UMLS CUI [3])
C0018939 (UMLS CUI [4])
C0024115 (UMLS CUI [5])
C0009450 (UMLS CUI [6])
C0151317 (UMLS CUI [7])
C0035309 (UMLS CUI [8])
C0087111 (UMLS CUI [9,1])
C0392760 (UMLS CUI [9,2])
C1261322 (UMLS CUI [9,3])
C0087111 (UMLS CUI [10,1])
C2348568 (UMLS CUI [10,2])
C0332196 (UMLS CUI [10,3])